FOLH1 and metastatic prostate carcinoma: An encouraging early data from trial of PSMA-specific CAR (NCT00664196) was demonstrated by Junghans (Junghans, 2012) at ASCO 2012 as two PR with a decrease in prostate specific antigen (PSA) levels and delayed disease progression were attained among five patients with metastatic prostate cancer who were treated with a non-myeloablative (NMA) conditioning regimen followed by either 109 or 1010 anti-PSMA CAR-T cells and IL-2 given by continuous infusion for 1 month alongside the T cell infusion.